Royalty Non Recurring vs Net Income From Continuing Ops Analysis
RPRX Stock | USD 27.41 1.02 3.87% |
Royalty PharmaPlc financial indicator trend analysis is much more than just breaking down Royalty PharmaPlc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Royalty PharmaPlc is a good investment. Please check the relationship between Royalty PharmaPlc Non Recurring and its Net Income From Continuing Ops accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty PharmaPlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Royalty Stock please use our How to Invest in Royalty PharmaPlc guide.
Non Recurring vs Net Income From Continuing Ops
Non Recurring vs Net Income From Continuing Ops Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Royalty PharmaPlc Non Recurring account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Royalty PharmaPlc's Non Recurring and Net Income From Continuing Ops is -0.25. Overlapping area represents the amount of variation of Non Recurring that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Royalty PharmaPlc, assuming nothing else is changed. The correlation between historical values of Royalty PharmaPlc's Non Recurring and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Recurring of Royalty PharmaPlc are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Non Recurring i.e., Royalty PharmaPlc's Non Recurring and Net Income From Continuing Ops go up and down completely randomly.
Correlation Coefficient | -0.25 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Non Recurring
Net Income From Continuing Ops
Most indicators from Royalty PharmaPlc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Royalty PharmaPlc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty PharmaPlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Royalty Stock please use our How to Invest in Royalty PharmaPlc guide.At this time, Royalty PharmaPlc's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to 0.00 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.06 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 51.4M | 5.7M | 5.1M | 4.8M | Interest Income | 53.5M | 78.3M | 72.3M | 45.0M |
Royalty PharmaPlc fundamental ratios Correlations
Click cells to compare fundamentals
Royalty PharmaPlc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Royalty PharmaPlc fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 12.4B | 21.1B | 17.5B | 16.8B | 16.4B | 17.2B | |
Other Current Liab | 9.2M | 297.1M | 165.6M | 161.4M | 146.2M | 153.5M | |
Total Current Liabilities | 333.4M | 307.9M | 171.3M | 1.2B | 161.4M | 132.4M | |
Total Stockholder Equity | 6.1B | 9.9B | 5.8B | 5.6B | 6.5B | 6.9B | |
Accounts Payable | 11.2M | 10.8M | 5.6M | 7.9M | 15.2M | 15.9M | |
Cash | 283.7M | 1.0B | 1.5B | 1.7B | 477.0M | 343.9M | |
Other Assets | 10.9B | 5.1B | 13.7B | 13.5B | 15.5B | 16.3B | |
Common Stock Shares Outstanding | 365.9M | 375.5M | 414.8M | 438.0M | 602.9M | 409.1M | |
Short Term Investments | 509.5M | 983M | 1.3B | 717.0M | 18.3M | 17.4M | |
Other Current Assets | 92K | 8.6M | 6.6M | 90.5M | 3.8M | 5.8M | |
Total Liab | 6.3B | 6.1B | 7.3B | 7.3B | 6.3B | 6.6B | |
Intangible Assets | 51.7M | 28.7M | 5.7M | 14.5M | 1.8M | 1.7M | |
Net Tangible Assets | 6.1B | 4.8B | 5.8B | 5.6B | 6.5B | 3.7B | |
Retained Earnings | 2.8B | 1.9B | 2.3B | 2.0B | 2.5B | 1.4B | |
Total Current Assets | 832.1M | 2.7B | 2.9B | 2.6B | 1.3B | 1.6B | |
Short Long Term Debt Total | 6.2B | 5.8B | 7.1B | 7.1B | 6.1B | 7.1B | |
Net Debt | 6.0B | 4.8B | 5.6B | 5.4B | 5.7B | 5.9B | |
Non Current Assets Total | 11.6B | 13.3B | 14.6B | 14.3B | 15.1B | 14.2B | |
Non Currrent Assets Other | 88.0M | 28.6M | 4.1M | 15.1M | 14.1B | 14.8B | |
Long Term Debt | 6.0B | 5.8B | 7.1B | 6.1B | 6.1B | 6.8B | |
Cash And Short Term Investments | 793.2M | 2.0B | 2.8B | 2.4B | 495.3M | 470.5M | |
Net Receivables | 38.8M | 39.2M | 68.3M | 36.6M | 775.1M | 813.8M | |
Long Term Debt Total | 6.0B | 5.8B | 7.1B | 6.1B | 7.0B | 6.9B | |
Liabilities And Stockholders Equity | 12.4B | 21.1B | 17.5B | 16.8B | 16.4B | 17.5B | |
Non Current Liabilities Total | 6.0B | 5.8B | 7.1B | 6.1B | 6.1B | 6.9B | |
Other Stockholder Equity | (4.3M) | 7.9B | 3.5B | 3.7B | 4.0B | 3.5B | |
Net Invested Capital | 12.3B | 10.6B | 12.9B | 12.7B | 12.7B | 13.2B | |
Long Term Investments | 11.5B | 13.0B | 14.4B | 14.1B | 15.1B | 14.1B | |
Accumulated Other Comprehensive Income | 2.1M | 34.4M | 16.5M | 63K | 72.5K | 68.8K | |
Net Working Capital | 498.7M | 2.4B | 2.7B | 1.4B | 1.1B | 1.3B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Royalty PharmaPlc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Royalty PharmaPlc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Royalty Pharmaplc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Royalty Pharmaplc Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty PharmaPlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Royalty Stock please use our How to Invest in Royalty PharmaPlc guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Royalty Stock analysis
When running Royalty PharmaPlc's price analysis, check to measure Royalty PharmaPlc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty PharmaPlc is operating at the current time. Most of Royalty PharmaPlc's value examination focuses on studying past and present price action to predict the probability of Royalty PharmaPlc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty PharmaPlc's price. Additionally, you may evaluate how the addition of Royalty PharmaPlc to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Royalty PharmaPlc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty PharmaPlc. If investors know Royalty will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Royalty PharmaPlc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Dividend Share 0.81 | Earnings Share 1.78 | Revenue Per Share 4.993 | Quarterly Revenue Growth (0.17) |
The market value of Royalty PharmaPlc is measured differently than its book value, which is the value of Royalty that is recorded on the company's balance sheet. Investors also form their own opinion of Royalty PharmaPlc's value that differs from its market value or its book value, called intrinsic value, which is Royalty PharmaPlc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Royalty PharmaPlc's market value can be influenced by many factors that don't directly affect Royalty PharmaPlc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Royalty PharmaPlc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Royalty PharmaPlc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Royalty PharmaPlc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.